A new Invokana side effects lawsuit was filed in U.S. District Court, District of New Jersey on Oct. 17, 2017. Plaintiffs Kyle S. and Jacqueline S. are citizens and residents of the state of North Dakota.

The defendants are Janssen Pharmaceuticals Inc. and its parent company Johnson & Johnson Inc.

With this Invokana side effects lawsuit, the plaintiffs are effectively joining multidistrict litigation no. 2750 which is pending in a federal court in New Jersey, where both defendants have their headquarters.

At issue with MDL 2750 is the drug Invokana, a type-2 diabetes drug designed, developed, promoted, and distributed by the defendants. The type-2 diabetic medication has purportedly led to numerous cases of Invokana amputation.

While amputation caused by diabetes is not uncommon due to the circulatory difficulties the long-term disease can pose, many patients that have been prescribed the diabetes treatment drug have made claims against the defendants believing that their exposure to the unique risks that are inherent and have been concealed by the two related companies have led to Invokana amputation.

According to the factual background in this Invokana side effects lawsuit, the U.S. Food and Drug Administration approved Invokana for domestic commercial distribution in March 2013.

Invokana is part of the sodium-glucose cotransporter 2 inhibitor (SGLT2) class of drugs whose aim is to lower blood glucose by inhibiting its re-absorption and ability to be metabolized. It does this by eliminating extra glucose through the kidneys which allegedly is supposed to reduce risks of the disease like heart disease, kidney disease, and amputation caused by diabetes.

Invokana Side Effects Lawsuit –The Experience of Kyle S.

Kyle S. alleges in his Invokana side effects lawsuit that the defendants knew about the “unreasonable risks” associated with this type-2 diabetes treatment drug, but that they have misrepresented and continue to misrepresent the benefits of taking the medication while concealing important information about adverse effects from patients and medical professionals.

He himself claims many personal injuries including Invokana amputation, ketoacidosis, kidney failure, stroke, and heart attack.

Kyle S. began taking Invokana, according to the narrative in this lawsuit, in March 2015. Shortly after starting the medication, he underwent multiple amputations. He attributes the need for these amputations to an increased risk of amputation associated with Invokana.

The couple is bringing the following counts against Janssen and Johnson & Johnson: Count One –Product Liability Act, Manufacturing Defect; Count Two –Product Liability Act, Defective Design; Count Three –Product Liability Act, Failure to Warn; Count Four –Breach of Express Warranty; Count Five –Breach of Warranty of Fitness for Ordinary Use; and Count Six –Negligence.

The couple is also bringing these additional counts against the defendants: Count Seven –Breach of Implied Warranty; Count Eight –Fraudulent Misrepresentation; Count Nine –Negligent Misrepresentation; Count Ten –Fraudulent Concealment; Count Eleven –Fraud; Count Twelve –Punitive Damages Allegations; and Count Thirteen –Loss of Consortium.

The plaintiffs are asking for compensatory damages in excess of the jurisdictional minimum of $75,000. They hope for medical costs and financial losses to be determined at trial. They are also asking for a return of all court and attorney costs as well as punitive damages.

The Invokana Amputation Lawsuit is Case No. 3:17-cv-08453-BRM-LHG in U.S. District Court for the District of New Jersey.